Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

The widely anticipated release of negotiated additions to the National Reimbursement Drug List by China’s National Medical Insurance Administration came on Nov. 28, with Innovent’s Tyvyt the lone anti-PD-1 mAb to make the cut. In all, 97 drugs were added to the list, including 74 drugs that aren’t traditional Chinese medicines.

Across the 52 newly-added innovative molecules to the NRDL, the average price cut was nearly 61%, higher than the 45% and 57% discounts negotiated for new drugs added to the NRDL in 2017 and 2018, respectively (see “China Releases Preliminary Reimbursement List”)...